Compare CENN & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENN | NXTS |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 9 |
| Industry | Auto Manufacturing | Agricultural Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.3K | 699.8K |
| IPO Year | 2017 | 2021 |
| Metric | CENN | NXTS |
|---|---|---|
| Price | $0.15 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 176.4K |
| Earning Date | 11-16-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,080,161.00 | $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $0.50 |
| 52 Week High | $4.84 | $53.90 |
| Indicator | CENN | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 17.25 | 30.01 |
| Support Level | $0.10 | $0.50 |
| Resistance Level | $4.54 | $0.79 |
| Average True Range (ATR) | 0.45 | 0.08 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 0.88 | 23.31 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, iChassis, Avantier, Teemak, Bison Motor, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the Europe, and also has a presence in America, Asia, and other regions.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.